Business Context and Reporting Period
Company: Coherus BioSciences, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: April 10, 2015
Event: Entry into a Material Definitive Agreement (Item 1.01)
Key Financial Metrics
This filing does not report revenue, profit, cash flow, margins, debt, or liquidity metrics. It discloses a specific contractual commitment:
- Contract Value: Up to approximately $22.9 million.
- Counterparty: A contract research organization (CRO).
- Purpose: Clinical study services for CHS-1420 (adalimumab biosimilar candidate).
- Study Scope: Phase 3 psoriasis study comparing CHS-1420 to Humira for efficacy and safety, planned to start in 2015.
Material Changes and Contract Terms
The filing details the execution of a Work Order under a Master Service Agreement (MSA) dated March 9, 2015. Key terms include:
- Termination Rights: Both Coherus and the CRO may terminate the MSA or Work Order with at least 90 days' written notice.
- Completion Obligation: If the CRO terminates while a Work Order is active, the MSA remains in force until services are completed and full payment is received.
- Breach Provisions: Material breaches must be cured within 30 days of notice; failure to cure allows immediate termination by the non-breaching party.
Guidance, Risks, and Contingencies
Confidentiality: Coherus intends to submit a request for confidential treatment to redact certain portions of the Work Order and MSA from public view.
Documentation: The full agreements will be filed as exhibits to the Form 10-Q for the fiscal quarter ended March 31, 2015.
Risk Factors: The filing does not explicitly list new risks beyond the standard contractual obligations and the inherent risks of clinical trial execution.
Investor Verification Checklist
- Verify the identity of the CRO and their track record with Phase 3 biosimilar trials.
- Review the upcoming Form 10-Q (Q1 2015) for the full text of the MSA and Work Order.
- Monitor the timeline for the initiation of the Phase 3 psoriasis study in 2015.
- Assess the impact of the $22.9 million commitment on the company's cash runway and liquidity.